Strain Background: C57BL/6N
Research & Application:
The humanized TNF-α mouse model allows in vivo efficacy and safety assessment of anti-human TNF-α compounds in the field of autoimmune diseases and inflammation.
Figure 1. Mean plasmatic concentrations of murine TNF-α and human TNF-α following LPS injection. Mean concentrations of murine TNF-α (A) and human TNF-α (B) measured by ELISA from plasma samples collected from WT (n=2) and KI (n=2) mice treated with saline solution vs. LPS.
Figure 2. ELISA analysis of humanized (red) and murine (blue) TNF-α expression. (Left) αCD3/αCD28 stimulated human peripheral blood mononuclear cells (hPMBC0 and (Right) wild-type or humanized TNF-α (hTNF-α) mouse spleen cells activated with αCD3/αCD28 (Act) or untreated (NA). After stimulated by αCD3/αCD28, humanized mouse peripheral blood mononuclear cells secrete humanized TNF-α (hTNF-α) instead of murine TNF-α (mTNF-α).
Figure 3. Humanized TNF-α (hTNF-α) and mouse TNF-α (mTNF-α) anti-proliferative activity. (Left) The supernatant of wild-type (mTNF-α) and hTNF-α mouse spleen cells activated by αCD3/αCD28 was collected to treat L929 cells. Compared with the supernatant of WT spleen cells, the supernatant of hTNF-α mice spleen cells used to treat L929 cells showed a concentration-dependent anti-proliferative phenotype of TNF-α. (Right) Pretreatment of wild-type mouse and hTNF-α mouse supernatants with murine and human TNF-α antibodies can relieve the inhibitory effect on L929 proliferation.